Wednesday, 26 August 2026European Markets

INTEROIL EXPL PROD Stock Was 13.01% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with INTEROIL EXPL PROD (IOX.OL) jumping 13.01% to kr0.66 on Monday while Oslo Børs Benchmark Index_GI rose 0.6% to kr1,273.99.

INTEROIL EXPL PROD's last close was kr0.58, 54.66% under its 52-week high of kr1.29.

About INTEROIL EXPL PROD

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-0.29.

Earnings Before Interest, Taxes, Depreciation, and Amortization

INTEROIL EXPL PROD's EBITDA is 26.84.

Moving Average

INTEROIL EXPL PROD's value is way below its 50-day moving average of kr0.75 and way below its 200-day moving average of kr0.88.

Revenue Growth

Year-on-year quarterly revenue growth declined by 41.7%, now sitting on 14.09M for the twelve trailing months.

More news about INTEROIL EXPL PROD (IOX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com